Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PHVS
PHVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PHVS News
Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73
Dec 06 2025
NASDAQ.COM
Stocks Rise on Hope for Fed Rate Cuts
Dec 03 2025
NASDAQ.COM
Stocks Bounce Back Amid Anticipation of Fed Rate Cuts
Dec 03 2025
NASDAQ.COM
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Dec 03 2025
Benzinga
Stocks Weaken Amid Labor Market Struggles and AI Demand Worries
Dec 03 2025
NASDAQ.COM
Pharvaris' Deucrictibant Significantly Reduces HAE Symptom Relief Time
Dec 03 2025
Globenewswire
Pharvaris' Phase 3 Study of Deucrictibant for On-Demand HAE Attack Treatment Achieves Important Milestones
Dec 03 2025
NASDAQ.COM
General Atlantic's $68 Million Investment: Insights into Pharvaris' Current Potential
Dec 03 2025
NASDAQ.COM
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?
Nov 18 2025
NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
Nov 18 2025
NASDAQ.COM
Top Analysts Recommend 3 Best Stocks to Purchase Now, 10/23/2025
Oct 23 2025
TipRanks
Pharvaris to Showcase Clinical Findings at the 2025 ACAAI Annual Scientific Meeting
Oct 23 2025
Newsfilter
Pharvaris N.V. (PHVS) Shares Insights at the 20th Annual Wells Fargo Healthcare Conference 2025 Transcript
Sep 05 2025
Newsfilter
Pharvaris N.V. (PHVS) Shares Transcript from 2025 Cantor Global Healthcare Conference
Sep 04 2025
Newsfilter
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Jul 23 2025
Newsfilter
Pharvaris Announces Acceptance of Abstracts for Presentation at 2025 US Hereditary Angioedema Association National Summit
Jun 27 2025
NASDAQ.COM
Show More News
